KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 1

Relationship between PK2 and number of Kupffer cells during the progression of liver fibrosis in patients with HBV

Xiao-Qin LIU
Rong-Rong WEI
Cheng-Cheng WANG
Li-Yu CHEN
Kai LIU
Cong LIU
Sayfa
52–61
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thus, PK2 most likely adjusts the number of M1 cells to modulate the role of KCs inthe progression of liver fibrosis after HBV infection.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: This study aimed to investigate the potential regulatory role of prokineticin 2 (PK2) in modulation of the number andfunction of Kupffer cells (KCs) during the progression of liver fibrosis in patients with hepatitis B virus (HBV).Materials and methods: We obtained liver tissue sections from 200 patients with HBV undergoing surgical resection in our hospitalbetween January 2013 and July 2016.
📊
Temel Bulgular & Veri:Of these 200 tissue sections, 150 were fibrosis tissues and 50 were hepatocellular carcinomatissues.
💡
Sonuç & Katkı:Thus, PK2 most likely adjusts the number of M1 cells to modulate the role of KCs inthe progression of liver fibrosis after HBV infection.
🔬Tür:Araştırma Makalesi
📍Kapsam:2013 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: This study aimed to investigate the potential regulatory role of prokineticin 2 (PK2) in modulation of the number andfunction of Kupffer cells (KCs) during the progression of liver fibrosis in patients with hepatitis B virus (HBV).Materials and methods: We obtained liver tissue sections from 200 patients with HBV undergoing surgical resection in our hospitalbetween January 2013 and July 2016. Of these 200 tissue sections, 150 were fibrosis tissues and 50 were hepatocellular carcinomatissues. Immunohistochemical evaluations were performed to assess the expression levels of CD68 and PK2 in the sections. The clinicalparameters of these 200 patients were also analyzed.Results: As a potential cytokine, PK2 was commonly expressed in KCs. In addition, a close correlation between PK2 and the number ofKCs during the progression of liver fibrosis in patients with HBV was found in this study.Conclusion: PK2 is expressed in KCs and participates in the progression of liver fibrosis after HBV infection. As a potential cytokine,PK2 modulates the number of KCs during fibrosis. Thus, PK2 most likely adjusts the number of M1 cells to modulate the role of KCs inthe progression of liver fibrosis after HBV infection.

🔖

Bu Makaleye Atıf Yap

LIU, X., WEI, R., WANG, C., CHEN, L., LIU, K., LIU, C. (2022). Relationship between PK2 and number of Kupffer cells during the progression of liver fibrosis in patients with HBV. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 1, 52–61. https://ajindex.com/articles/610385

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
  2. Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroentero 2014; 20: 10395-10404.
  3. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14: 181-194.
  4. Kisseleva T, Brenner DA. The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. J Hepatol 2012; 56: 965-972.
  5. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028- 1040. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol 2016; 13: 316-327.
  6. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218. 8. Wells RG. Mechanisms of liver fibrosis: new insights into an old problem. Drug Discov Today 2006; 3: 489-495.
  7. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206. 10. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003; 38 (Suppl. 1): S38-53. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014; 60: 1090-1096.
  8. Elsegood CL, Chan CW, Degli-Esposti MA, Wikstrom ME, Domenichini A, Lazarus K, van Rooijen N, Ganss R, Olynyk JK, Yeoh GC. Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration. Hepatology 2015; 62: 1272-1284.
  9. Monnier J, Samson M. Cytokine properties of prokineticins. FEBS J 2008; 275: 4014-4021.
  10. Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P, Screpanti I, Balboni G, Salvadori S, Sacerdote P, Negri L. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. P Natl Acad Sci USA 2009; 106: 14646-14651.
  11. Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, Negri L, Sacerdote P. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol 2006; 147: 225-234.
  12. Melchiorri D, Bruno V, Besong G, Ngomba RT, Cuomo L, De Blasi A, Copani A, Moschella C, Storto M, Nicoletti F et al. The mammalian homologue of the novel peptide Bv8 is expressed in the central nervous system and su